Evaluation of GLR2007 for Advanced Solid Tumors

A Study of Gimatecan (ST1481) in Small Cell Lung Cancer

NCT04501029 ·Status: UNKNOWN ·Phase: PHASE2

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

NCT06908772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT00344773 ·Status: COMPLETED ·Phase: PHASE2

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

NCT07303881 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

NCT04338243 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

NCT06092086 ·Status: RECRUITING ·Phase: PHASE2

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

NCT06634667 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

NCT00770588 ·Status: COMPLETED ·Phase: PHASE4

GIOTRIF rPMS in Korean Patients With NSCLC

NCT02285361 ·Status: COMPLETED

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

NCT04028778 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

NCT03976856 ·Status: UNKNOWN ·Phase: PHASE1

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

NCT01819428 ·Status: TERMINATED ·Phase: PHASE2

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

NCT01588145 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

NCT06109558 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

NCT02691767 ·Status: COMPLETED ·Phase: NA

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT04044170 ·Status: TERMINATED ·Phase: PHASE2

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

NCT07330596 ·Status: RECRUITING ·Phase: PHASE2

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT02040870 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

NCT04339829 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NCT06361927 ·Status: RECRUITING ·Phase: PHASE2

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

NCT03059797 ·Status: COMPLETED ·Phase: PHASE2